Search clinical trials for: Influenza, H5N1, vaccine, avian influenza

Total 3677 results

UMN Pharma Inc.

Completed

Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults

Virus Diseases | Influenza

Japan
Centers for Disease Control and Prevention

Unknown

Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety Study of Avian Flu Vaccine

Influenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | Orthomyxoviridae | H5N1 Virus

United States
VaxInnate Corporation

Completed

Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

Influenza

United States
Novavax
Department of Health and Human Services

Completed

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1

Influenza (Pandemic)

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

Influenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | H5N1 Virus | Orthomyxovirdae

United States
National Institute of Allergy and Infectious Diseases...
Emory University

Completed

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

Influenza A Virus, H5N1 Subtype

United States
Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
Emergent BioSolutions

Completed

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Influenza | Bird Flu

United States
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions

Influenza, Human

Germany
Medigen Biotechnology Corporation

Completed

A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine

Avian Influenza | Bird Flu | Influenza A(H5N1)

Taiwan
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
Novartis Vaccines

Completed

Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine

Avian Influenza

Italy
Novavax
Department of Health and Human Services

Completed

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

Influenza (Pandemic)

United States
National Institute of Allergy and Infectious Diseases...

Completed

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

Influenza A Virus, H5N1 Subtype

United States
Seqirus

Completed

A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine

Influenza, Human

Estonia, Philippines
Institute of Vaccines and Medical Biologicals,...
Department of Health and Human Services; Institut Pasteur; PATH; World Health Organization

Completed

Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1

Influenza A Subtype H5N1 Infection

Vietnam
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
Biomedical Advanced Research and Development Authority
PPD

Completed

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

A/Vietnam/H5N1 Influenza Virus

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Development of Immune Globulin Treatment for Avian Flu

Influenza | Infectious Diseases | Avian Flu

United States
GlaxoSmithKline

Completed

Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults

Influenza | Influenza Vaccines

Taiwan, Hong Kong, Thailand, Singapore
IDRI
Defense Advanced Research Projects Agency; Medicago

Completed

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

Influenza A Subtype H5N1 Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

Orthomyxoviridae Infections | Pandemic Influenza | Influenza A Virus Infection

Belgium
Vaxart

Completed

Safety Study of an Oral Vaccine to Prevent Avian Influenza (H5N1)

Avian Influenza | Bird Flu

United States
National Institute of Allergy and Infectious Diseases...

Completed

Experimental AD4-H5-VTN Vaccine in Healthy Volunteers

H5N1 Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects

Pandemic H5N1 Influenza

Poland, Turkey
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 (Clade 2) Vaccination of Adults and Elderly

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines

Influenza

United States
GlaxoSmithKline
United States Department of Health and Human Services, Center for Disease...

Withdrawn

Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

Influenza

United States
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

Pandemic H5N1 Influenza

United States, Australia, Thailand
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

Influenza

United States, Canada
VaxInnate Corporation

Completed

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Mix and Match With AS03

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine

H5N1 Influenza

United States
Ology Bioservices
Baxter Innovations GmbH

Completed

H5N1 Vaccine Study in Japanese Adults

H5N1 Influenza

Japan
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

Influenza

United States, Canada
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age

Influenza

Germany
UMN Pharma Inc.

Completed

Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults

Influenza

Japan
Intercell USA, Inc.
Department of Health and Human Services

Completed

A/H5N1 Dose Ranging Study With Adjuvant Patch

Pandemic Influenza

United States
AVIR Green Hills Biotechnology AG
Medical University of Vienna

Completed

Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults (GHB-CS03)

Influenza

Austria
National Institute of Allergy and Infectious Diseases...

Completed

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

China Case Control Avian Influenza

Influenza

China
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Priming and Boosting Strategies

Influenza

United States
GlaxoSmithKline

Completed

A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64

Influenza

Canada
Adimmune Corporation

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

Pandemic Influenza

Taiwan
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Pandemic H5N1 Influenza

United States, Australia, New Zealand, Thailand
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

Pandemic H5N1 Influenza

United States, Thailand
GlaxoSmithKline

Completed

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

Influenza | Influenza Vaccines

United States, Thailand, Canada

Search clinical trials for: Influenza, H5N1, vaccine, avian influenza

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations